Brief Summary: Treatment of the autoimmune and immune-dysregulatory features of patients with STAT1 GOF or STAT3 GOF disease remains challenging. Jakinibs have been used to treat the severe immune-dysregulation in patients with either STAT1 GOF or STAT3 GOF mutations.
All Keywords
【저자키워드】 Tocilizumab, ruxolitinib, Stat1, HLH, Tofacitinib, STAT3, Jakinib,
【저자키워드】 Tocilizumab, ruxolitinib, Stat1, HLH, Tofacitinib, STAT3, Jakinib,